Is a Beat in Store for BioNTech (BNTX) This Earnings Season?

On BioNTech’s (BNTX) third-quarter earnings call, investors’ focus is expected to be on the sales performance of Comirnaty, its COVID-19 vaccine developed in partnership with Pfizer.

Leave a comment

Your email address will not be published. Required fields are marked *